Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Would you administer adjuvant chemotherapy for extrahepatic cholangiocarcinoma that has received neoadjuvant therapy and achieved near CR?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · The START Center for Cancer Care

If the regimen was well-tolerated and there is reason to believe that additional treatment could have been administered (preop tumor evaluation was not stalled out, suggesting ongoing response), I would favor additional therapy. You may also have a role for ctDNA monitoring but I know many are not i...

How would you approach a completely resected DLBCL of the appendix if PET scan and bone marrow biopsy suggest no other disease?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Stanford University

Resected limited stage DLBCL has relatively high risk of recurrence. A recent prospective phase II trial was reported (Yoon et al. Oncotarget 2017) where patients received 3 cycles of RCHOP post resection and had an excellent 2 year PFS of 95%. Another study (Sehn et al. Annals of Oncology 2008 abst...

What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?

3 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Northwestern University Feinberg School of Medicine

Currently, there are no standard criteria used to choose CAR-T over conventional stem cell transplant as destination therapy. However, there are many factors that often push us in one direction or the other. As we learn more about outcomes after CAR-T cell therapy, there are many factors we know are...

What are your top takeaways in Hematologic Malignancies from ASH 2024?

12 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Texas Southwestern Medical Center

Abstract 1009 - Multiple important studies were presented at the recently concluded ASH meeting. From the CLL perspective, one of the most impactful studies was the AMPLIFY clinical trial that compared acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-li...

Do you use G-CSF for a patient with ALL admitted for febrile neutropenia with prolonged count recovery?

2 Answers

Mednet Member
Mednet Member
Hematology · Montefiore

Acknowledging the lack of definitive data, in our group we use G-CSF as primary prophylaxis in adult patients with ALL treated with intensive chemotherapy and hardly ever need to re-administered if they develop FN subsequently. That said, for prolonged neutropenia despite prior G-CSF, we may adminis...

Do you commonly observe acute erythrocytosis in patients with ILD flares being treated with supplemental oxygen and high-dose corticosteroids?

1
1 Answers

Mednet Member
Mednet Member
Hospital Medicine · University of California San Francisco

Assuming that this patient does not have erythrocytosis at baseline, my experience is that acute erythrocytosis is not typical. Erythrocytosis caused by hypoxemia typically has a lag of several weeks, even though EPO increases within 48 hours. You commonly see a moderate acute leukocytosis with high...

What is your clinical threshold for treating a potential monoclonal gammopathy of thrombotic significance?

1
1 Answers

Mednet Member
Mednet Member
Hematology · University of Wisconsin

I strongly advise against routine screening for monoclonal gammopathy in patients with thrombosis. The incidence of MGUS, particularly in older patients, is relatively high and so the signal-to-noise ratio in this setting will be very low. In a patient with recurrent thrombosis and thrombocytopenia ...

How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?

1
1 Answers

Mednet Member
Mednet Member
Hematology · UMass Chan Medical School

Not sure of the current platelet count? Not sure of the age of the patient.Will still use antiplatelet therapy for acute stroke as advised.Support with platelet transfusion as needed for platelet count <20. Hopefully patient responds to HMA and venetoclax, and platelet counts improve.If in CR by mar...

How would you manage aplastic anemia refractory to multiple agents?

1 Answers

Mednet Member
Mednet Member
Hematology · Dana-Farber Cancer Institute

If indeed the patient has been treated with all reasonable alternatives to BMT, the choices are 1) watch and wait with supportive care or 2) bone marrow transplantation. I understand the reluctance of transplanting someone in their 70s with aplastic anemia; however, we do this routinely in patients ...

What is your preferred therapy for MDS/MPN with significant leukocytosis and neutrophilia?

1 Answers

Mednet Member
Mednet Member
Hematology · UMass Chan Medical School

Depends on blast count, cytogenetics, and molecular test results, age of patient, performance status, comorbidities, etc. To bring the white count down can temporarily start with hydroxyurea. would use induction chemo versus HMA +/- venetoclax to achieve at least a partial response. can be a candida...